Samphire Neuroscience is a London-based neurotechnology company building drug-free, hormone-free wearables for women's health. Its flagship product, Nettle, is a headband that uses transcranial direct current stimulation (tDCS) to gently modulate the brain regions tied to mood and pain, worn 20 minutes a day in the run-up to menstruation. Marketed as the first EU-cleared (CE-certified) neuromodulation device for women's health, Nettle targets PMS, PMDD, menstrual pain and related hormonal conditions. Founded in 2021 by neuroscientist Emilė Radytė and IP lawyer Alex Cook, the company has raised roughly $7.77M across pre-seed, seed and Series A rounds.
Dimension Bio (formerly Dimension Inx) is a Chicago-based regenerative therapeutics company that turns living cells into implantable, tissue-like therapies. Its BioNidum platform fuses materials science, 3D printing, and digital manufacturing to build three-dimensional microenvironments that help transplanted cells survive, vascularize, and function in the body. A Northwestern University spinout, the company already brought the first FDA-cleared 3D-printed regenerative bone graft (CMFlex) to patients and is now aiming its lead program at acute liver failure - building an engineered, mini-liver-like therapy to stabilize patients and give their own organs a chance to recover.
Axoft is a Cambridge, Massachusetts neurotechnology company building implantable brain-computer interfaces (iBCIs) out of Fleuron, a proprietary material it claims is up to 10,000x softer than the polyimide used in conventional brain implants. By making electronics roughly as soft as brain tissue, Axoft aims to keep thousands of sensors in stable contact with single neurons for years instead of months - reducing scarring and signal loss - to diagnose and eventually treat disorders of consciousness, paralysis, and other neurological conditions. A Harvard spinout founded in 2021, it raised an oversubscribed $55M Series A in April 2026 and has run first-in-human studies in 11+ patients worldwide.